NIAID Launches First Clinical Trial to Test Antibody–Drug Combination for Long-Acting HIV Treatment

The AIDS Clinical Trials Group, funded by the National Institute of Allergy and Infectious Diseases (NIAID), has started the first clinical trial testing a combined method of anti-HIV antibodies plus a long-acting antiretroviral medication as long-acting HIV treatment. Researchers are exploring the use of HIV antibodies for their potential to stop a wide variety of HIV strains from infecting immune cells. The implications of a long-acting HIV treatment could make viral suppression more realistic for those who have difficulty taking a daily drug regimen.

Read more about the clinical trial on

About Kim Rodgers

Kim Rodgers serves as a Communications Specialist at NACCHO. Her work includes promoting local health departments' best practices, as well as partner tools and resources, in infectious disease and preparedness through NACCHO's communications channels, storytelling, and outreach to various audiences.

Leave a Reply

Your email address will not be published. Required fields are marked *